Alnylam Pharmaceuticals Company

Covid-relevant. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished scientific leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics – ONPATTRO (patisiran) in 2018 and GIVLAARI® (givosiran) in 2019. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Technology: AgeTech Companies
Industry: Covid-19
Headquarters: United Kingdom
Founded Date: 2002-01-01
Employees Number: 1001-5000
Funding Status: IPO
Investors Number: 11
Total Funding: 2500000000
Estimated Revenue: $100M to $500M
Last Funding Date: 2020-04-13
Last Funding Type: Post-IPO Debt

Visit Website
Register and Claim Ownership